Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Pharma deals pivot from high-risk modalities, targets

BioCentury’s analysis of 12 months of dealmaking between biotechs and top pharmas

By Lauren Martz, Executive Director, Biopharma Intelligence
August 24, 2024 12:38 AM UTC

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

The past 12 months have brought a surge in pharma dealmaking, and with that comes evidence of changes in external innovation objectives among the top pharmas. The first-in-class strategies that have defined dealmaking in recent years are giving way to best-in-class priorities. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Bristol Myers Squibb Co.

Pfizer Inc.